1 option
Pharmacoeconomic review report : indication: for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency. Cerliponase Alfa (Brineura) (BioMarin Pharmaceutical (Canada) Inc.) / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Language:
- English
- Subjects (All):
- Cost effectiveness.
- Physical Description:
- 1 online resource (33 pages) : illustrations
- Edition:
- Final (with redactions).
- Place of Publication:
- Ottawa (ON) : CADTH, 2019.
- Summary:
- Cerliponase alfa (Brineura) is a solution for administration by intracerebroventricular (ICV) infusion that is currently under review by Health Canada with a proposed indication for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl-peptidase-1 deficiency. The manufacturer's reimbursement request was as per the indication. The recommended dosage for cerliponase alfa is 300 mg (10 mL solution) administered every other week by ICV infusion for people aged two years or older. It is available in 150 mg/5 mL vials at a price of 2,380.33 for a package of two vials (16,190.17 per vial). The annual cost per patient aged two years or older is
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.